retatrutide clinical trial obesity Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished retatrutide triple hormone receptor agonist
Description
Some GLP-1 medications come with additional FDA-approved benefits
Some practitioners do prescribe phentermine alongside GLP-1 receptor agonists
Endocrinology 146: 458462, 2005
The injectable versus oral peptide comparison explains why injectable delivery remains the gold standard for GLP-1 medications
Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the study of diabetes
Your medication ships from a licensed compounding pharmacy
